By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Neuralink wants to protect implants from interference.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
Bioprospecting for genes of new species in the world’s oceans has become complex and extremely lucrative.
The company’s stock ran higher after the company buoyed investors’ hopes that its technology will boost a lineup of new popular drugs.
The growing sector scored its second-highest month ever for total money-raising.
Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.
Blue Origin is going slower than SpaceX, but it also nailed a massive rocket launch on the first try. Jeff Bezos is back in the space race.
The listing marks a potentially triumphant comeback story and an insult of sorts to the embattled London stock exchange.
With the way things are going today, it’s becoming increasingly hard to figure out what’s going on with the oil market.